Dexamethasone Treatment Considerably Reduces the Levels of Some Inflammatory Cytokines, Lactate Dehydrogenase, and C-Reactive Protein in COVID-19 Pneumonia Patients With Pre-existing COPD

Background: Dexamethasone is the most widely used corticosteroid for treating COVID-19 pulmonary complications. The effects of dexamethasone on serum inflammatory factors, including C-reactive protein (CRP), lactate dehydrogenase (LDH), and cortisol, were evaluated in COVID-19 pneumonia patients wit...

Full description

Saved in:
Bibliographic Details
Main Authors: Gholamreza Sepehri, Zeinab Fallah, Mitra Samareh Fekri, Behnam Dalfardi, Shahriar Dabiri, Hamid Daneshvar, Mohammad Javad Najafzadeh
Format: Article
Language:English
Published: Kerman University of Medical Sciences 2024-10-01
Series:Journal of Kerman University of Medical Sciences
Subjects:
Online Access:https://jkmu.kmu.ac.ir/article_92258_c596ba0c22ae9cc1147fb7cdd650caf8.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Dexamethasone is the most widely used corticosteroid for treating COVID-19 pulmonary complications. The effects of dexamethasone on serum inflammatory factors, including C-reactive protein (CRP), lactate dehydrogenase (LDH), and cortisol, were evaluated in COVID-19 pneumonia patients with pre-existing chronic obstructive pulmonary disease (COPD) in this study.Methods: A total of 36 COVID-19 patients with pneumonia who had pre-existing COPD and were critically ill and 56 COVID-19- positive patients without pre-existing COPD were selected. A daily dose of 6–8 mg dexamethasone was administered during the hospitalization period. Some inflammatory markers (TNF-α, IL-10, and IL-6) and the serum levels of cortisol, LDH, and CRP were measured on admission and one week after hospitalization.Results: TNF-α and IL-6 concentrations were significantly reduced and IL-10 significantly increased in all COVID-19 pneumonia patients with or without pre-existing COPD as a result of a daily dose of dexamethasone. Also, a significant reduction in cortisol, CRP, and LDH was observed following dexamethasone administration in all COVID-19 pneumonia patients, with or without preexisting COPD, with no correlation with gender, cigarette or waterpipe smoking, or opium abuse.Conclusion: Our results showed a significant increase in TNF-α, IL-6, IL-10, cortisol, LDH, and CRP and a significant reduction in IL-10 in all critically ill COVID-19 pneumonia patients. Dexamethasone administration significantly reduced cortisol and proinflammatory cytokines and also LDH and CRP as the markers of COVID-19 severity.
ISSN:1023-9510
2008-2843